Chargement en cours...
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody developed and approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. Ongoing trials are investigating the use of risankiz...
Enregistré dans:
| Publié dans: | Clin Pharmacokinet |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7051925/ https://ncbi.nlm.nih.gov/pubmed/31758502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00842-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|